Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 223 member B (FAM223B) is classified as a long intergenic non-protein coding RNA (lincRNA), implicated in gene regulation at the transcriptional, post-transcriptional, or epigenetic level[3][4][8]. FAM223B is a non-protein coding gene also referred to as LINC00204B, encoding a lincRNA transcript rather than a protein. While lincRNAs can control gene expression programs and have roles in development, cell differentiation, and disease states, there is no direct evidence for a therapeutic target function or specific disease association for FAM223B. Current knowledge does not establish FAM223B as involved with drug mechanisms, biomarker selection, or clinical safety challenges[3][4][8]. Note: Some of the aliases and database entries may contain closely related gene symbols typical for non-coding RNA annotation, but no conflicts or major errors are detected in the form or spelling of this target. FAM223B is indexed as a non-protein coding gene, not as a receptor, enzyme, or other canonical drug target class[3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 223 member B (non-protein coding) (FAM223B).